Large multicentre rheumatoid arthritis DCE-MRI study published

Bioxydyn’s DCE-MRI is better at detecting early differences between drug effects in rheumatoid arthritis than other options.
17 February 2017

A new publication in European Radiology deomonstrates the sensitivity of DCE-MRI in distinguishing treatments in rheumatoid arthritis of the hand and wrist as early as 6 weeks after commencing treatment. Bioxydyn's Imaging Services team provided site qualification, site training, quality control and data analysis for this study, which is one of the largest to employ standardised DCE-MRI in a multicentre setting with full tracer kinetic modelling. The work was sponsored by AstraZeneca and involved 32 imaging centres in three continents. Bioxydyn believe that this study sets the bar for multicentre DCE-MRI in RA.

Full citation (open access): J.C. Waterton, M. Ho, L.H. Nordenmark, M. Jenkins, J. DiCarlo, G. Guillard, C. Roberts, G. Buonaccorsi, G.J.M. Parker, M.A. Bowes, C. Peterfy, H. Kellner, P.C. Taylor. Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. European Radiology. (In press) http://doi.org/10.1007/s00330-017-4736-9

Bioxydyn news link: http://www.bioxydyn.com/news?article=39